Key result
Trimetazidine added to standard medical therapy did not significantly improve left ventricular ejection fraction, exercise capacity, mortality, or quality of life in patients with stable advanced HFrEF.
Why the study?
Trimetazidine modulates cardiac metabolism, but its use in heart failure remains controversial.
Does trimetazidine improve LVEF, exercise capacity, and quality of life in patients with stable advanced HFrEF on standard medical therapy?
Comparison
Trimetazidine (35 mg b.i.d.) on top of standard medical therapy vs standard pharmacotherapy alone
Design
Prospective, single-center, open-label, cross-over randomized study
Follow-up
6 months
Authors
Loading...
Does not support trimetazidine addition in stable advanced HFrEF; confirms no incremental benefit on LVEF or outcomes.
RCT (n=45)
Open-label
Computer-generated random list
No
Does trimetazidine improve LVEF, exercise capacity, and quality of life in patients with stable advanced HFrEF on standard medical therapy?
Absolute Event Rate: 26.7% vs 24.6%
p-value: p=0.059
The addition of trimetazidine to standard medical therapy in patients with stable advanced HFrEF does not significantly improve LVEF, exercise capacity, quality of life, or cardiovascular outcomes.
Bohdan et al. (2020) conducted an RCT in Stable advanced chronic heart failure with reduced left ventricular ejection fraction (HFrEF) (n=45). Trimetazidine vs. Standard medical therapy was evaluated on Change in mean left ventricular ejection fraction (LVEF) (p=0.059). Trimetazidine added to standard medical therapy did not significantly improve left ventricular ejection fraction, exercise capacity, mortality, or quality of life in patients with stable advanced HFrEF.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: